Loading stock data…
$87.55-0.19 (-0.22%)
CVS Health Corporation provides health solutions in the United States.
CVS Health Corporation in the Healthcare sector is trading at $87.55 with a market capitalization of $123.7B. Wall Street consensus targets $115.48 (25 analysts), implying a +31.9% move over the next 12 months. The stock is currently 21% below its 52-week high of $110.68, remaining 0.3% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $106.10B↑ | $100.43B↓ | $105.69B↑ | $102.87B↑ | $98.92B |
| Gross Profit | $15.75B↑ | $15.62B↑ | $13.57B↓ | $13.81B↑ | $13.59B |
| Operating Income | $4.70B↑ | $4.68B↑ | $2.11B↓ | $2.52B↑ | $2.38B |
| Net Income | $2.98B↑ | $2.94B | $2.94B↑ | -$3.98B↓ | $1.02B |
CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and beha...
Academic risk and quality models computed from CVS's own filings and price history, not from analyst opinion.
Mixed: 6 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z in the 1.81 to 2.99 grey zone, the band where the model gives no clear bankruptcy verdict.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, below the current 30.1% reading.
Fama-French 5-factor market beta. The five factors explain 6% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-10-13.